Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Edding Genor Group HoldingsHKSE:06998 +0.33%15 ROE % is 12.92% as of Dec. 2025, which is 11% below its 10-year median of 14.51. GuruFocus rates HKSE:06998 with a GF Score™ of 15/100. The stock has 1 warning sign investors should review. Among 935 Drug Manufacturers companies, Edding Genor Group Holdings ranks better than 73.48% on this metric.
Edding Genor Group Holdings (HKSE:06998) ROE % Explanation
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is one times the annual (Dec. 2025) net income data. The Revenue data used here is one times the annual (Dec. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Edding Genor Group Holdings ROE % Chart
Edding Genor Group Holdings Annual Data
Trend
Dec24
Dec25
ROE %
16.10
12.92
Edding Genor Group Holdings Semi-Annual Data
Dec24
Dec25
ROE %
16.10
12.92
HKSE:06998 vs ZTS: ROE % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Edding Genor Group Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Edding Genor Group Holdings ROE % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Edding Genor Group Holdings's ROE % distribution charts can be found below:
* The bar in red indicates where Edding Genor Group Holdings's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is one times the annual (Dec. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Edding Genor Group Holdings (HKSE:06998) has a ROE % of 12.92% as of Dec. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Edding Genor Group Holdings and its competitors. This is 11% below median its historical median of 14.51. Over the past decade, Edding Genor Group Holdings' ROE % has ranged from 12.92 to 16.10. According to the industry distribution chart, Edding Genor Group Holdings ranks #248 out of 935 companies in the Drug Manufacturers industry, placing it in the top 26.5%.
Is Edding Genor Group Holdings' ROE % too high?
Edding Genor Group Holdings' current ROE % of 12.92% is 11% below median its 10-year median of 14.51. Over the past 10 years, this metric has ranged from a low of 12.92 to a high of 16.10. The Drug Manufacturers industry median ROE % is 6.14. Edding Genor Group Holdings' value of 12.92% is 110.4% above this industry median. Based on the distribution chart, Edding Genor Group Holdings ranks #248 out of 935 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Edding Genor Group Holdings has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Edding Genor Group Holdings' ROE % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Edding Genor Group Holdings ranks #248 out of 935 companies for ROE %. This puts Edding Genor Group Holdings in the upper half of its industry. The industry median ROE % is 6.14. Edding Genor Group Holdings' value of 12.92% is 110.4% above this benchmark. Historically, Edding Genor Group Holdings' own ROE % has ranged from 12.92 to 16.10 over the past decade. While the company's 10-year median is 14.51 vs. the industry median of 6.14, Edding Genor Group Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Drug Manufacturers company?
The median ROE % among Drug Manufacturers companies is 6.14, based on 935 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Edding Genor Group Holdings's current ROE % of 12.92% is 110.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Edding Genor Group Holdings and its competitors. For the Drug Manufacturers industry, the median ROE % is 6.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Edding Genor Group Holdings's current ROE % is 12.92%, which is 11% below median its own 10-year median of 14.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edding Genor Group Holdings stock overvalued right now?
Edding Genor Group Holdings (HKSE:06998) has a current ROE % of 12.92%. The current ROE % is 12.92%, which is 11% below median its 10-year median of 14.51 and 110.4% above the Drug Manufacturers industry median of 6.14. Edding Genor Group Holdings' overall GF Score™ is 15/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Edding Genor Group Holdings (HKSE:06998), the current ROE % is 12.92% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Edding Genor Group Holdings Ltd is an integrated specialty biopharmaceutical company, focusing on oncology, autoimmune diseases, cardiovascular diseases, respiratory diseases, and anti-infectives. Through the acquisition of branded drug assets from multinational pharmaceutical companies (MNCs) and licensing in development and commercialisation rights of patented drugs from international biopharmaceutical companies, it has established a portfolio of originator-branded and other drugs. The company has two reportable operating segments: Manufacturing and Distribution, which generates the maximum revenue, and Research and development. Geographically, it derives maximum revenue from the Chinese mainland, and the rest from the USA and other markets.
15GF Score
Get the complete analysis for HKSE:06998
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:06998 has been successfully added to your 
